| 0.19 0.007 (3.6%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.34 | 1-year : | 0.46 |
| Resists | First : | 0.29 | Second : | 0.39 |
| Pivot price | 0.26  |
|||
| Supports | First : | 0.14 | Second : | 0.11 |
| MAs | MA(5) : | 0.18 |
MA(20) : | 0.28 |
| MA(100) : | 0.55 |
MA(250) : | 1.02 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19 |
D(3) : | 15.5 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 2.78 | Low : | 0.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IOBT ] has closed above bottom band by 22.5%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.2 - 0.2 | 0.2 - 0.2 |
| Low: | 0.17 - 0.17 | 0.17 - 0.17 |
| Close: | 0.19 - 0.19 | 0.19 - 0.19 |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Fri, 13 Feb 2026
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing - Yahoo Finance
Fri, 30 Jan 2026
IO Biotech (IOBT) launches restructuring, CMO exit and up to $2.6M charges - Stock Titan
Mon, 26 Jan 2026
IO Biotech stock tumbles after Piper Sandler downgrades on strategic review - Investing.com
Mon, 26 Jan 2026
Piper Sandler Downgrades IO Biotech (IOBT) to Neutral, Lowers Pr - GuruFocus
Thu, 22 Jan 2026
IOBT IO Biotech, Inc. (NASDAQ) $0.47 on 22 Jan 2026: active intraday mover for traders - Meyka
Wed, 21 Jan 2026
IO Biotech stock plummets after company explores strategic alternatives - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 46.7 (%) |
| Shares Short | 4,260 (K) |
| Shares Short P.Month | 3,080 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -88.6 % |
| Return on Equity (ttm) | -240.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.15 |
| PEG Ratio | 0 |
| Price to Book value | 19 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|